Suppression of androgen receptor and activation of apoptotic signaling pathway in the prostate cancer LNCaP cells: The synergistic effect of Epigallocatechin-3-gallate and conditioned medium derived from WJ-MSCs

Although there were several approaches to treat Prostate cancer (PCa), the cost and side effects of some of them have encountered the patients with challenges. Therefore, the design of new therapy methods could be useful in the management of this disease. For this purpose, the synergic effect of Epigallocatechin gallate (EGCG) and conditioned medium derived from Wharton's jelly mesenchymal stem cells (WJ-MSCs) were studied on prostate cancer LNCaP cells. In this study, LNCaP cells were treated with different concentrations of EGCG and conditioned medium derived from WJ-MSCs (WJCM). The viability of treated cells was determined by using MTT assay. Then, the expression of androgen receptor (AR and PSA) and apoptotic (BAX, CASP3 and CASP7) pathway genes were defined by Real time PCR. The analysis of the data indicated that the treatment with 400µM EGCG in combination with 50% WJCM (0% FBS) for 72 hours decreased expression of AR and PSA genes as well as the enhanced expression of BAX, CASP3 and CASP7 genes in the LNCaP cells (p < 0.05). The obtained results suggested that the combination therapy of EGCG and WJCM had an anticancer effect on LNCaP cells through activation of apoptotic pathway and suppression of androgen receptor pathway.